Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

A Deptor Inhibitor Induces Its Degradation with Resulting Anti-Myeloma Cytotoxicity in Vitro and In Vivo

Mario I Vega, PhD, Yijiang Shi, MD PhD, Patrick Frost, PhD, Sara Huerta-Yepez, PhD, Alan Lichtenstein, MD

Blood (2019) 134 (Supplement_1): 1821.

https://doi.org/10.1182/blood-2019-121480

Published: 2019

Journal Articles

Deptor As a Target with Chemical Inhibitors; Alternative Therapy in Multiple Myeloma

Mario Vega, PhD, Patrick Frost, PhD, Carolyne Bardeleben, PhD, Yijiang Shi, MD PhD, Sara Huerta-Yepez, PhD, Alan Lichtenstein, MD

Blood (2017) 130 (Supplement 1): 3833.

https://doi.org/10.1182/blood.V130.Suppl_1.3833.3833

Published: 2017

Journal Articles

Evaluating the Efficacy and Toxicity of Two Lenalidomide Dose Regimens for the Treatment of Older Relapsed Multiple Myeloma Patients with Co-Morbidities: A Multi-Site Study at the Veteran's Administration Hospitals

Sarvari V Yellapragada, MD, Shayna Sarosiek, MD, Neelima D Prabhala, B.A., Mehmet Kemalsamur, PhD, Antoun Houranieh, RPh., M.S., PhD, Saulius Girnius, MD, Praveen Tumula, MD, Suman Kambhampati, MD, Nirmala Bhoopalam, MD, Rao H Prabhala, PhD, David Roodman, MD, PhD, Alan Lichtenstein, MD, Nikhil C Munshi, MD

Blood (2015) 126 (23): 5370.

https://doi.org/10.1182/blood.V126.23.5370.5370

Published: 2015

Journal Articles

Mechanism Of Anti-Myeloma Effects Due To Silencing Of Deptor

Yonghui Yang, PhD, Alan Lichtenstein, MD

Blood (2013) 122 (21): 4428.

https://doi.org/10.1182/blood.V122.21.4428.4428

Published: 2013

Journal Articles

Anti-CD138-IFNα Fusion Proteins Are Effective in Treating Multiple Myeloma

Esther Yoo, PhD, Alex Vasuthasawat, Danh Tran, Alan Lichtenstein, MD, Sherie Morrison, PhD

Blood (2012) 120 (21): 939.

https://doi.org/10.1182/blood.V120.21.939.939

Published: 2012

Journal Articles

Targeting Deptor in Multiple Myeloma

Yonghui Yang, Joseph Gera, Alan Lichtenstein, MD

Blood (2012) 120 (21): 575.

https://doi.org/10.1182/blood.V120.21.575.575

Published: 2012

Journal Articles

Identification and Characterization of Inhibitors That Specifically Target TORC2 in Multiple Myeloma

Bao Hoang, Joseph Gera, Alan Lichtenstein, MD

Blood (2012) 120 (21): 5026.

https://doi.org/10.1182/blood.V120.21.5026.5026

Published: 2012

Journal Articles

Membrane Lipid Biosynthesis As a Potential Therapeutic Target in Multiple Myeloma

Carolyne Bardeleben, Alan Lichtenstein, MD

Blood (2012) 120 (21): 1836.

https://doi.org/10.1182/blood.V120.21.1836.1836

Published: 2012

Journal Articles

Characterization of Hepcidin-Inducing Cytokines in Multiple Myeloma.

Ken Maes, Alissa Huston, MD, David Roodman, MD, PhD, Seth Rivera, MD, PhD, Elizabeta Nemeth, PhD, Alan Lichtenstein, MD, Karin Vanderkerken, PhD, Tomas Ganz, MD, PhD

Blood (2009) 114 (22): 2001.

https://doi.org/10.1182/blood.V114.22.2001.2001

Published: 2009

Journal Articles

Interleukin-6 (IL-6) Enhances C-MYC Translation IN MULTIPLE MYELOMA (MM) CELLS: ROLE of IL-6-INDUCED EFFECTS On the C-MYC RNA-Binding PROTEIN, HNRNPA1.

Yijiang Shi, Joseph Gera, Alan Lichtenstein, MD

Blood (2009) 114 (22): 3839.

https://doi.org/10.1182/blood.V114.22.3839.3839

Published: 2009

Journal Articles

Aberrant Splicing of the E-Cadherin Gene Is a Novel Mechanism of Gene Silencing in Chronic Lymphocytic Leukemia Cells

Sanjai Sharma, MD, MB, BS, Alan Lichtenstein, MD

Blood (2008) 112 (11): 2842.

https://doi.org/10.1182/blood.V112.11.2842.2842

Published: 2008

Journal Articles

Dexamethasone Induced Apoptotic Mechanisms in Myeloma Cells by Analysis of Mutant Glucocorticoid Receptors.

Sanjai Sharma, MD, Alan Lichtenstein, MD

Blood (2007) 110 (11): 2492.

https://doi.org/10.1182/blood.V110.11.2492.2492

Published: 2007

Journal Articles

The Role of AKT and ERK in Regulating D-Cyclin Translation Inhibition and G1 Arrest in Multiple Myeloma Cells Treated with mTOR Inhibitors: Rationale for Combination Thereapy.

Patrick J. Frost, PhD, YiJiang Shi, MD, Carolyne Bardalaban, PhD, Bao Hoang, PhD, Alan Lichtenstein, MD

Blood (2007) 110 (11): 4795.

https://doi.org/10.1182/blood.V110.11.4795.4795

Published: 2007

Journal Articles

Hepcidin Overproduction Mediates the Anemia of Multiple Myeloma.

Sanjai Sharma, MD, Elizabeta Nemeth, Ph.D, Yi-Hsiang Chen, MD, Alissa Huston, MD, G.D. Roodman, MD, Julia Goodnough, Tomas Ganz, MD, Alan Lichtenstein, MD

Blood (2006) 108 (11): 516.

https://doi.org/10.1182/blood.V108.11.516.516

Published: 2006

Journal Articles

AKT Kinase Addiction in Multiple Myeloma.

Carolyne Bardeleben, PhD, Huajun Yan, PhD, Patrick Frost, PhD, Bao Hoang, PhD, Yijiang Shi, MD, PhD, Sanjai Sharma, MD, Alan Lichtenstein, MD

Blood (2006) 108 (11): 3431.

https://doi.org/10.1182/blood.V108.11.3431.3431

Published: 2006

Journal Articles

Targeting Aurora Kinases as Therapy in Multiple Myeloma.

Yijiang Shi, PhD, Tony Reiman, MD, Weiqun Li, PhD, Christopher Maxwell, PhD, Linda Pilarski, PhD, Rick Feldman, PhD, Alan Lichtenstein, MD

Blood (2006) 108 (11): 3484.

https://doi.org/10.1182/blood.V108.11.3484.3484

Published: 2006

Journal Articles

Premature Termination Codon Mutations in Chronic Lymphocytic Leukemia (CLL): Identification of Potential Tumor Suppressors in CLL Including E-Cadherin.

Sanjai Sharma, MD, Alan Lichtenstein, MD

Blood (2005) 106 (11): 2935.

https://doi.org/10.1182/blood.V106.11.2935.2935

Published: 2005

Journal Articles

Anti-Angiongenic Effects of mTOR-Inhibitors Is Regulated by AKT Activity in Multiple Myeloma Cells.

Patrick Frost, PhD, Bao Hoang, PhD, Yijiang Shi, MD, Huajun Yan, PhD, Alan Lichtenstein, MD

Blood (2005) 106 (11): 3406.

https://doi.org/10.1182/blood.V106.11.3406.3406

Published: 2005

Journal Articles

Mechanism by Which mTOR Inhibitors Sesitize Multiple Myeloma Cells to Dexamethasone-Induced Apoptosis.

Huajun Yan, PhD, Patrick Frost, PhD, Yijiang Shi, MD & PhD, Bao Hoang, PhD, Sanjai Sharma, MD, Myrna Fisher, Joseph Gera, PhD, Alan Lichtenstein, MD

Blood (2005) 106 (11): 1582.

https://doi.org/10.1182/blood.V106.11.1582.1582

Published: 2005

Journal Articles

AKT Activity Regulates Sensitivity of Multiple Myeloma Cells to mTor Inhibitors.

Patrick Frost, Ph.D., Bao Hoang, Ph.D., Joseph Gera, Ph.D., Anushree Sharma, Yijiang Shi, Ph.D., Huajun Yan, Ph.D., Alan Lichtenstein, MD.

Blood (2004) 104 (11): 646.

https://doi.org/10.1182/blood.V104.11.646.646

Published: 2004

NARROW

A Deptor Inhibitor Induces Its Degradation with Resulting Anti-Myeloma Cytotoxicity in Vitro and In Vivo

Deptor As a Target with Chemical Inhibitors; Alternative Therapy in Multiple Myeloma

Evaluating the Efficacy and Toxicity of Two Lenalidomide Dose Regimens for the Treatment of Older Relapsed Multiple Myeloma Patients with Co-Morbidities: A Multi-Site Study at the Veteran's Administration Hospitals

Mechanism Of Anti-Myeloma Effects Due To Silencing Of Deptor

Anti-CD138-IFNα Fusion Proteins Are Effective in Treating Multiple Myeloma

Targeting Deptor in Multiple Myeloma

Identification and Characterization of Inhibitors That Specifically Target TORC2 in Multiple Myeloma

Membrane Lipid Biosynthesis As a Potential Therapeutic Target in Multiple Myeloma

Characterization of Hepcidin-Inducing Cytokines in Multiple Myeloma.

Interleukin-6 (IL-6) Enhances C-MYC Translation IN MULTIPLE MYELOMA (MM) CELLS: ROLE of IL-6-INDUCED EFFECTS On the C-MYC RNA-Binding PROTEIN, HNRNPA1.

Aberrant Splicing of the E-Cadherin Gene Is a Novel Mechanism of Gene Silencing in Chronic Lymphocytic Leukemia Cells

Dexamethasone Induced Apoptotic Mechanisms in Myeloma Cells by Analysis of Mutant Glucocorticoid Receptors.

The Role of AKT and ERK in Regulating D-Cyclin Translation Inhibition and G1 Arrest in Multiple Myeloma Cells Treated with mTOR Inhibitors: Rationale for Combination Thereapy.

Hepcidin Overproduction Mediates the Anemia of Multiple Myeloma.

AKT Kinase Addiction in Multiple Myeloma.

Targeting Aurora Kinases as Therapy in Multiple Myeloma.

Premature Termination Codon Mutations in Chronic Lymphocytic Leukemia (CLL): Identification of Potential Tumor Suppressors in CLL Including E-Cadherin.

Anti-Angiongenic Effects of mTOR-Inhibitors Is Regulated by AKT Activity in Multiple Myeloma Cells.

Mechanism by Which mTOR Inhibitors Sesitize Multiple Myeloma Cells to Dexamethasone-Induced Apoptosis.

AKT Activity Regulates Sensitivity of Multiple Myeloma Cells to mTor Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only